Referral:
MD (neurologist)
Patient association
Community (from social media)
Self referral

inclusion and exclusion criteria for PD and control group

Consent for longitudinal cohort study and enrollment

Baseline assessment

18 months assessment

48 months assessment

Primary Outcomes
Diagnosis of MCI**, Dementia**, apathetic syndrome, Major depression

Secondary Outcomes
Index of Motor impairment (dopamine responsive and unresponsive symptoms)
Disabling dyskinesia or motor fluctuation
Freezing of gait

Surrogate outcome
Brain volume loss (Quantitative volumetric MRI)

Outcome measures
Neuropsychological evaluation
CANTAB
MoCA
PD-CRS
TMT-A and TMT-B
SDMT
WAIS-III digits and similarities

Non-motor symptoms
NMSS
MDS-UPDRS Paris I & II
BDI, BSI
HADS
PDSS-BR
RBDSQ
SAS
QUIP-CS and QUIP-RS
PD-CFRS

Motor symptoms
MDS-UPDRS Paris III & IV
Quality of life
PDQ-8

Demographic data:
Diagnosis and co-morbidities*
Age*
Gender
Disease duration*
Disease subtype*
Treatments*

* at all time points

Neuroimaging biomarker
MRI (3T): DTI, 3D T1 TFE, 3D FLAIR

** Assessing DSM- V, MDS and Winblad criteria